Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma

Cancer Genetics and Cytogenetics

Volumn 127, Issue 2, 2001, Pages 93-110

  Sandberg, Avery A ^a   Bridge, Julia A ^b  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS;

BONE TUMOR; CHROMOSOME; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MOLECULAR GENETICS; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SIMIAN VIRUS 40; SOFT TISSUE TUMOR;

ANIMALS; BONE NEOPLASMS; CYTOGENETICS; EUROPE; GENOMICS; GREAT BRITAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MESOTHELIOMA; MOLECULAR BIOLOGY; SOFT TISSUE NEOPLASMS;

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0034960144     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(01)00432-0     Document Type: Review

References (173)

1. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
2. The European mesothelioma epidemic
3. Analysis of current trends in United States mesothelioma incidence
4. Cytopathology of pleural mesothelioma
5. The separation of benign and malignant mesothelial proliferations
6. The role of immunohistochemistry in the diagnosis of malignant mesothelioma
7. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
8. Severe chromosomal aberrations in pleural mesothelioma with unusual mesodermal features
9. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines
10. Mesothelioma and mineral fibers
11. Asbestos; scientific development and implications for public policy
12. Malignant mesothelioma; attributable risk of asbestos exposure
13. Lung carcinoma and malignant mesothelioima in patients exposed to thorotrast; Incidence, histology and p53 status
14. Malignant mesothelioma; Clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients
15. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species
16. Crocidolite asbestos induces apoptosis of pleural mesothelial cells; role of reactive oxygen species and poly(ADP-ribosyl) polymerase
17. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma
18. Asbestos and mesothelioma; genetic lessons from a tragedy
19. Simian virus 40-like DNA sequences in human pleural mesothelioma
20. Establish of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma
21. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma
22. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers
23. The molecular basis of asbestos induced lung injury
24. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma
25. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma
26. Homozygous deletion within chromosome region 9p21-p22 in human malignant mesotheliomas
27. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma
28. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas
29. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma
30. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma
31. Tumor suppressor genes in malignant mesothelioma
32. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma
33. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma
34. Somatic genetic alterations in human malignant mesothelioma (review)
35. Recurring loss involving chromosomes 1, 3 and 22 in malignant mesothelioma; possible sites of tumor suppressor genes
36. Cytogenetic analysis of malignant mesothelioma
37. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors
38. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma
39. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma
40. Nonrandom chromosome alterations in human malignant mesothelioma
41. Recurrent chromosome 6 abnormalities in malignant mesothelioma
42. del(6q) as a possible primary change in malignant mesothelioma
43. Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma
44. Translocation X;12 in mesothelioma
45. Chromosomes changes in malignant mesothelioma
46. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology
47. Interphase cytogenetics on paraffin sections of malignant pleural mesothelioma. A comparison to conventional karyotyping and flow cytometric studies
48. Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopic in situ hybridization
49. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization
50. Chromosomal abnormalities in human malignant mesothelioma
51. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization
52. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity
53. A cell cycle regulator potentially involved in genesis of many tumor types
54. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma
55. Codeletion of p15 and p16 in primary malignant mesothelioma
56. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma
57. INK4a cyclin-dependent kinase inhibitor in malignant mesothelioma
58. INK4a in mesothelioma cell results in cell cycle arrest, cell death, tumor suppression and tumor regression
59. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer
60. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
61. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma; evidence for a two-hit mechanism of NF2 inactivation
62. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma
63. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas
64. p53 and Kirsten-ras mutations in human mesothelioma cell lines
65. Tumour-suppressor genes. Open questions on p16
66. Absence of p53 mutations in malignant mesotheliomas
67. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelioma
68. p53 expression is common in malignant mesothelioma
69. The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas
70. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
71. Physical and functional interaction between WT1 and p53 proteins
72. 1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes
73. Wilms' tumor suppressor gene expression in rat and human mesothelioma
74. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
75. Expression of the Wilms' tumour gene WT 1 in human malignant mesothelioma cell lines
76. Lack of expression of the retinoblastoma gene is not frequently involved in the genesis of human mesothelioma
77. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
78. Simian virus-40 large-T antigen binds p53 in human mesotheliomas
79. New molecular and epidemiological issues in mesothelioma; role of SV40
80. Cell and molecular biology of SV40; implications for human infections and diseases
81. SV40 induces mesotheliomas in hamsters
82. Cancer risk associated with simian virus 40 contaminated poliovaccine
83. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers
84. An old acquaintance resurfaces in human mesothelioma
85. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas
86. Simian virus 40, poliovaccines and human tumors; a review of recent developments
87. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas
88. Simian virus 40 large antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue
89. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas
90. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases
91. Molecular biology studies on mesothelioma tumor samples; preliminary data on H-Ras, P21, and SV40
92. Further validation of SV40-like DNA in human pleural mesotheliomas
93. Simian virus 40 and human pleural mesothelioma
94. SV40, JC and BK expression in tissue, urine and blood samples from patients with malignant and nonmalignant pleural disease
95. Simian virus 40 and pleural mesothelioma in humans
96. Simian virus 40 (SV40)-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines
97. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ
98. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma
99. Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors
100. Gap junctional intercellular communication of primary and asbestos-associated malignant mesothelial cells
101. Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells
102. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cell lines in vitro
103. Regional assignment of seven loci to 12p13.2-pter by PCR analysis of somatic cell hybrids containing the der(12) or the der(X) chromosome from a mesothelioma showing t(X;12)(q22;p13)
104. A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13)
105. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma
106. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules
107. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
108. Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma
109. Absence of BCL10 mutations in human malignant mesothelioma
110. Absence of HHV-8 DNA sequences in malignant mesothelioma
111. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2); in vitro antiproliferative effects of a COX-2 inhibitor
112. Modulation of integrin expression on mesothelioma; the role of different histotypes in invasiveness
113. Expression of E-cadherin in bone and soft tissue sarcomas; a possible role in epithelial differentiation
114. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma
115. Translocation (2;3)(p21;p26) as the sole anomaly in a benign localized fibrous mesothelioma
116. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma
117. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma
118. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma
119. Mesothelioma and lung carcinomas
120. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells
121. N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. A ThinPrep® immunocytochemical study
122. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma
123. Asbestos-related malignant mesothelioma; growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients
124. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma
125. Calretinin; a novel immunocytochemical marker for mesothelioma
126. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura
127. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma
128. NCAM (Neural Cell Adhesion Molecules) expression in malignant mesotheliomas
129. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression cell-type transition, and prognosis
130. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma
131. The immunohistochemical diagnosis of epithelial mesothelioma
132. Anti-MOC-31; a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel
133. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung
134. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma
135. Emerging translational therapies for mesothelioma
136. Detection of SV40 sequences in human mesothelioma
137. Identification par denaturation thermique menagee des anomalies chromosomiques observees dans six tumeurs metastatiques humaines
138. Chromosome changes in soft tissue sarcomas
139. Chromosomes and chromosomal evolution in human mesotheliomas as reflected in sequential analyses of two cases
140. Specificity of chromosomal aberrations in human malignant mesotheliomas
141. Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma; a case report
142. Human malignant mesothelioma cell lines express PDGF β-receptors whereas cultured normal mesothelial cells express predominantly PDGF α-receptors
143. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β-integrin α3β1 interaction
144. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines; interleukin-6 production as a common feature
145. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma
146. Angiogenic cytokines in mesothelioma; a study of VEGF, FGF-1 and -2, and TGFβ expression
147. Chemotaxis and haptotaxis of human malignant mesothelioma cells; effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance
148. 1 integrins
149. Tenascin and fibronectin expression in human mesothelial cells and pleural mesothelioma cell-line cells
150. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor
151. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines
152. Gene expression profiling of malignant mesothelioma cell lines; cDNA array study
153. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
154. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders
155. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene
156. Absence of post-transcriptional RNA modifications of BCL10 in human malignant mesothelioma and colorectal cancer
157. Control of cell cycle progression in human mesothelioma cells treated with gamma interferon
158. Serum-dependent growth patterns of two, newly established human mesothelioma cell lines
159. Benign and malignant mesothelial proliferations
160. Expression and prognostic significance of catalase in malignant mesothelioma
161. Immunopathology of malignant mesothelioma (MM) and pulmonary adenocarcinoma
162. An assessment of the value of several markers for the differential diagnosis of pleural mesothelioma and pulmonary adenocarcinoma
163. Simian virus 40 DNA sequences are not common in human malignant mesothelioma. A PCR analysis using paraffin tissues
164. Mesothelioma subsets consistently express epidermal growth factor receptor (EGFR), but not Her-2-neu; an immunohistochemical study
165. Expression of telomerase reverse transcriptase (TERT) in malignant mesothelioma
166. Peritoneal mesothelioma - occupation and mineral fibre analysis